Company Profile
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Latest News
IBM Fell 25% as Hardware Spending Dominated AI Budgets. Palantir Sells What Runs on Top.
Dow Jones Futures Rise, Oil Prices Dive On Iran Hopes; Apple Leads Earnings Wave, Fed Meeting Ahead
Kevin Warsh Wanted a ‘Family Feud’ at the Fed; At Wednesday’s Meeting He Might Get One
China's industrial profit growth moderates as exports cushion uneven recovery
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://samsungbiologics.com |
| Audit Risk | 1 |
| Board Risk | 5 |
| Overall Risk | 4 |
| Market Cap | 71.94T |
| Enterprise-to-Revenue | 14.5 |
| Enterprise-to-EBITDA | 25.07 |
| Earnings Date | 07/23/2026 |
| Earnings Call Date | |
| Earnings Average | 9,718 |
| Earnings Low | 8,964.8 |
| Earnings High | 10,666.02 |
| Revenue Average | 1.33T |
| Revenue Low | 1.27T |
| Revenue High | 1.38T |